Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase I

This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the
safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose
(RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1
checkpoint inhibitor (CPI) pembrolizumab (Keytruda).
Phase I
Davis, Elizabeth

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: